Trial Profile
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Bintrafusp alfa (Primary) ; Temozolomide (Primary) ; Topotecan (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 27 Jan 2024 Planned primary completion date changed from 15 Jan 2024 to 15 Jan 2025.
- 23 Dec 2021 Status changed from suspended to recruiting.
- 19 Oct 2021 Status changed from recruiting to suspended.